ABCG2 transports anticancer drugs via a closed-to-open switch.
Benjamin J OrlandoMaofu LiaoPublished in: Nature communications (2020)
ABCG2 is an ABC transporter that extrudes a variety of compounds from cells, and presents an obstacle in treating chemotherapy-resistant cancers. Despite recent structural insights, no anticancer drug bound to ABCG2 has been resolved, and the mechanisms of multidrug transport remain obscure. Such a gap of knowledge limits the development of novel compounds that block or evade this critical molecular pump. Here we present single-particle cryo-EM studies of ABCG2 in the apo state, and bound to the three structurally distinct chemotherapeutics. Without the binding of conformation-selective antibody fragments or inhibitors, the resting ABCG2 adopts a closed conformation. Our cryo-EM, biochemical, and functional analyses reveal the binding mode of three chemotherapeutic compounds, demonstrate how these molecules open the closed conformation of the transporter, and establish that imatinib is particularly effective in stabilizing the inward facing conformation of ABCG2. Together these studies reveal the previously unrecognized conformational cycle of ABCG2.
Keyphrases
- molecular dynamics simulations
- cancer stem cells
- healthcare
- crystal structure
- induced apoptosis
- genome wide
- single cell
- radiation therapy
- squamous cell carcinoma
- dna methylation
- drug resistant
- signaling pathway
- blood pressure
- gene expression
- case control
- heart rate variability
- binding protein
- drug induced
- endoplasmic reticulum stress
- transcription factor
- rectal cancer
- electronic health record
- adverse drug
- chronic myeloid leukemia